カテゴリー： MarketsandMarkets, 世界, 医療/バイオ

世界のワクチン市場（～2028年）：技術別（遺伝子組換え、トキソイド、コンジュゲート、RNA）、種類別（単価、多価）、疾患別（肺炎球菌、インフルエンザ、DTP、HPV、MMR、新型コロナウイルス感染症）、投与経路別（IM、SC、経口）、エンドユーザー別（小児、成人）、地域別

◆英語タイトル：Vaccines Market by Technology (Recombinant, Toxoid, Conjugate, RNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Influenza, DTP, HPV, MMR, COVID-19), Route of Administration (IM, SC, Oral), End user (Pediatric, Adult) & Region - Global Forecast to 2028
	◆商品コード：PH6528-23 ◆発行会社（リサーチ会社）：MarketsandMarkets ◆発行日：2023年11月8日 ◆ページ数：371 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後24時間以内） ◆調査対象地域：グローバル ◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD4,950 ⇒換算￥742,500	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥997,500	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥1,222,500	見積依頼/購入/質問フォーム

★MarketsandMarketsに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

“世界のワクチン市場規模は2023年の776億米ドルから2028年には938億米ドルに達し、予測期間中の年平均成長率は3.9％と予測”伝染病の高い発生率、ワクチン技術の革新、ワクチン開発に対する政府の支援と多額の資金援助、ワクチン接種イニシアチブの高まり、革新的なワクチンへの投資と上市への強い注力などの要因です。

“結合型ワクチン分野がワクチン市場で圧倒的なシェアを獲得”
ワクチン技術に基づき、世界のワクチン市場は不活化・サブユニットワクチン、弱毒生ワクチン、トキソイドワクチン、ウイルスベクターワクチン、組み換えワクチン、結合型ワクチンに区分されます。コンジュゲートワクチンは大きなCAGRで成長すると予測されています。結合型ワクチン開発分野における企業の投資と相まって、政府の支援が拡大し、官民の協力体制が強化されていることが、市場の成長に好影響を与えると考えられます。

“肺炎球菌セグメントが2022年の疾患適応症セグメントで最大シェアを占める”
疾患適応症に基づき、ワクチン市場は、混合ワクチン、HPV、髄膜炎菌性疾患、帯状疱疹、ロタウイルス、MMR、肺炎球菌性疾患、インフルエンザ、水痘、肝炎、DTP、ポリオ、その他の疾患適応症に区分されます。2022年には、肺炎球菌セグメントがワクチン市場で最大のシェアを占めました。肺炎球菌感染症患者の増加、ワクチン接種プログラムに対する政府投資の増加など、様々な要因により、同セグメントが市場で圧倒的なシェアを占めています。

“アジア太平洋はワクチン市場においてより速いペースで成長する可能性が高い”
ワクチン市場の地域は、北米、ヨーロッパ、アジア太平洋、中南米、中東、アフリカに区分されます。アジア太平洋は、予測期間中に大きなCAGRで成長すると予測されています。同地域の成長は、ワクチン開発に対する政府支援の増加、アジア諸国における医療支出の増加、伝染病の出現と再出現、可処分所得の増加などの恩恵を受け、アジア太平洋への投資を増やしている企業によるところが大きい。

本レポートのために実施した一次インタビューは以下のように分類されます：
- 回答者別：供給側 - 80％、需要側 - 20％
- 回答者の役職別（供給側）：管理職 - 45％、CXO・取締役 - 30％、経営幹部 - 25％
- 地域別：北米 - 40％、ヨーロッパ - 25％、アジア太平洋 - 20％、中南米 - 10％、中東 - 4％、アフリカ - 1％

レポート掲載企業一覧：
• GSK plc (UK)
• Merck & Co., Inc. (US)
• Pfizer, Inc. (US)
• Sanofi (France)
• CSL (Australia)
• Emergent (US)
• Johnson & Johnson Services Inc. (US)
• AstraZeneca (UK)
• Serum Institute of India Pvt. Ltd. (India)
• Bavarian Nordic (Denmark)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Daiichi Sankyo Company, Limited (Japan)
• Panacea Biotec (India)
• Biological E. Limited (India)
• Bharat Biotech (India)
• Novavax (US)
• Inovio Pharmaceuticals (US)
• Sinovac (China)
• Incepta Pharmaceuticals (Bangladesh)
• Valneva SE (France),
• VBI Vaccines Inc. (US)
• Bio Farma (Indonesia)
• FSUE NPO Microgen (Russia)
• Zhi fei Biological (China)
• Indian Immunologicals Ltd (India)

調査範囲：
本レポートは、ワクチン市場の詳細な情報を提供します。技術、タイプ、適応疾患、投与経路、エンドユーザー、地域など、さまざまなセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの企業プロフィールや最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点：
本レポートは、ワクチン市場全体とそのサブセグメントにおける売上高に最も近い概算値を提供することで、市場リーダーや新規参入者を支援します。また、利害関係者が競争状況をよりよく理解し、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるための洞察を深めるのにも役立ちます。本レポートにより、関係者は市場の動向を把握し、主要な市場促進要因、阻害要因、機会、課題に関する情報を得ることができます。

本レポートは、以下のポイントに関する洞察を提供します：
- 主な促進要因（新規ワクチンへの投資と上市の重視、感染症流行の増加、予防接種プログラムの拡大、ワクチン技術の進歩、ワクチン開発に対する政府の強力な支援と資金提供）、阻害要因（高い開発コスト、特許切れ）、機会（治療用ワクチンへの注目の高まり、強固で強力なパイプライン）、課題（規制プロセスの厳格化、ワクチン供給不足、頻繁な製品回収）が臨床試験用品市場の成長に影響を与えていることを分析します。
- 製品開発/イノベーション：ワクチン市場の新発売製品に関する詳細な洞察を記載しています。
- 市場開発：有利な市場に関する包括的情報 - 当レポートでは、さまざまな地域のワクチン市場を分析しています。
- 市場の多様化：ワクチン市場における新サービス、未開拓地域、最新動向、投資に関する詳細情報を掲載しています。
- パイプライン分析：臨床試験中の製品に関する包括的な情報を掲載しています。
- 競合評価： GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark)などの主要企業の市場シェア、成長戦略、サービス提供についての詳細な評価を提供しています。

1.　イントロダクション
2.　調査方法
3.　エグゼクティブサマリー
4.　プレミアムインサイト
5.　市場概要
6.　世界のワクチン市場規模：技術別
7.　世界のワクチン市場規模：種類別
8.　世界のワクチン市場規模：疾患別
9.　世界のワクチン市場規模：投与経路別
10.　世界のワクチン市場規模：エンドユーザー別
11.　世界のワクチン市場規模：地域別
12.　競争環境
13.　企業情報
14.　付録

❖ レポートの目次 ❖

1 INTRODUCTION 44
1.1 STUDY OBJECTIVES 44
1.2 MARKET DEFINITION 44
1.3 INCLUSIONS & EXCLUSIONS 45
1.4 MARKET SCOPE 45
1.4.1 MARKETS COVERED 45
1.4.2 REGIONS COVERED 46
1.4.3 YEARS CONSIDERED 46
1.4.4 CURRENCY CONSIDERED 46
1.5 RESEARCH LIMITATIONS 47
1.6 STAKEHOLDERS 47
1.7 SUMMARY OF CHANGES 48
1.8 RECESSION IMPACT: VACCINES MARKET 48
2 RESEARCH METHODOLOGY 49
2.1 RESEARCH DATA 49
2.2 RESEARCH APPROACH 49
FIGURE 1 RESEARCH DESIGN 49
2.2.1 SECONDARY DATA 50
2.2.2 PRIMARY DATA 51
FIGURE 2 BREAKDOWN OF PRIMARIES 51
2.2.2.1 Primary insights 52
FIGURE 3 KEY INSIGHTS FROM PRIMARY EXPERTS 52
2.3 MARKET SIZE ESTIMATION 53
FIGURE 4 MARKET SIZE ESTIMATION: VACCINES MARKET, 2022 53
FIGURE 5 TOTAL REVENUE: VACCINES MARKET 54
FIGURE 6 REVENUE SHARE OF PFIZER INC., 2022 54
2.3.1 SEGMENTAL ASSESSMENT 55
FIGURE 7 TOP-DOWN APPROACH 55
2.4 GROWTH RATE ASSUMPTIONS 57
FIGURE 8 CAGR PROJECTION: VACCINES MARKET 57
FIGURE 9 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 58
2.5 STUDY ASSUMPTIONS 58
2.6 MARKET BREAKDOWN AND DATA TRIANGULATION 59
FIGURE 10 DATA TRIANGULATION METHODOLOGY 59
2.7 RISK ASSESSMENT 60

2.8 IMPACT OF RECESSION IN VACCINES MARKET 60
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024–2028 (% GROWTH) 61
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 61
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 61
3 EXECUTIVE SUMMARY 62
FIGURE 11 VACCINES MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION) 62
FIGURE 12 VACCINES MARKET, BY TYPE, 2023 VS. 2028 (USD BILLION) 63
FIGURE 13 VACCINES MARKET, BY DISEASE INDICATION, 2023 VS. 2028 (USD BILLION) 64
FIGURE 14 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD BILLION) 65
FIGURE 15 VACCINES MARKET, BY END USER, 2023 VS. 2028 (USD BILLION) 65
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF VACCINES MARKET 66
4 PREMIUM INSIGHTS 68
4.1 VACCINES MARKET OVERVIEW 68
FIGURE 17 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 68
4.2 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY AND COUNTRY, 2022 69
FIGURE 18 M-RNA VACCINES AND US ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN VACCINES MARKET IN 2022 69
4.3 VACCINES MARKET, BY TECHNOLOGY, 2023 VS. 2028 70
FIGURE 19 M-RNA VACCINES TO DOMINATE MARKET IN 2028 70
4.4 GEOGRAPHICAL GROWTH OPPORTUNITIES: VACCINES MARKET 70
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 70
5 MARKET OVERVIEW 71
5.1 INTRODUCTION 71
5.2 MARKET DYNAMICS 71
FIGURE 21 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: VACCINES MARKET 71
TABLE 4 IMPACT ANALYSIS: VACCINES MARKET 72
5.2.1 DRIVERS 72
5.2.1.1 Strong emphasis on launch of novel vaccines 72
5.2.1.2 Rising prevalence of infectious diseases 73
FIGURE 22 INCIDENCE OF TUBERCULOSIS IN US, 2017–2021 74
5.2.1.3 Increasing number of immunization programs 74
5.2.1.4 Advancements in vaccine technology 75
5.2.1.5 Robust government support and funding for vaccine development 75
TABLE 5 NIH FUNDING FOR VACCINE RESEARCH, 2020–2024 (USD MILLION) 76
5.2.2 RESTRAINTS 76
5.2.2.1 High cost of vaccine development 76

5.2.3 OPPORTUNITIES 77
5.2.3.1 Increased focus on therapeutic vaccines 77
5.2.3.2 Extensive R&D for vaccines and increased investments in clinical trials 77
5.2.4 CHALLENGES 78
5.2.4.1 Stringent regulatory processes 78
5.2.4.2 Frequent product recalls 78
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 79
FIGURE 23 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR VACCINE PROVIDERS 79
5.4 PRICING ANALYSIS 79
5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYERS 79
TABLE 6 AVERAGE SELLING PRICE OF PEDIATRIC VACCINES 79
TABLE 7 AVERAGE SELLING PRICE OF ADULT VACCINES 81
5.4.2 AVERAGE SELLING PRICE, BY PRODUCT TYPE 82
TABLE 8 AVERAGE SELLING PRICE OF CONJUGATE VACCINES 82
TABLE 9 AVERAGE SELLING PRICE OF RECOMBINANT VACCINES 82
TABLE 10 AVERAGE SELLING PRICE OF INACTIVATED & SUBUNIT VACCINES 83
TABLE 11 AVERAGE SELLING PRICE OF LIVE ATTENUTAED VACCINES 83
TABLE 12 AVERAGE SELLING PRICE OF TOXOID VACCINES 84
TABLE 13 AVERAGE SELLING PRICE OF M-RNA VACCINES 84
5.4.3 AVERAGE SELLING PRICE TREND 85
5.5 TECHNOLOGY ANALYSIS 85
5.6 VALUE CHAIN ANALYSIS 85
FIGURE 24 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES TO CONTRIBUTE MAXIMUM VALUE 86
5.7 PIPELINE ANALYSIS 87
FIGURE 25 CLINICAL TRIALS IN VACCINES MARKET 87
FIGURE 26 VACCINES MARKET IN CLINICAL TRIALS, BY DISEASE INDICATION 87
TABLE 14 PIPELINE PRODUCTS UNDER PHASE-2 AND PHASE-3 CLINICAL TRIALS 88
5.7.1 KEY PIPELINE PRODUCTS 91
TABLE 15 KEY PIPELINE VACCINES: GSK PL 91
TABLE 16 KEY PIPELINE VACCINES: MERCK & CO., INC. 91
TABLE 17 KEY PIPELINE VACCINES: PFIZER, INC. 91
TABLE 18 KEY PIPELINE VACCINES: SANOFI S.A. 91
5.8 ECOSYSTEM MARKET/MAP 92
FIGURE 27 ECOSYSTEM MARKET/MAP 92
TABLE 19 ROLE IN ECOSYSTEM: VACCINES MARKET 92
5.9 REGULATORY ANALYSIS 93
5.9.1 REGULATORY LANDSCAPE FOR VACCINES 93
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97
TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97
TABLE 24 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
TABLE 25 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
5.10 PORTER’S FIVE FORCES ANALYSIS 98
TABLE 26 PORTER’S FIVE FORCES ANALYSIS 98
5.10.1 THREAT OF NEW ENTRANTS 99
5.10.2 THREAT OF SUBSTITUTES 99
5.10.3 BARGAINING POWER OF SUPPLIERS 99
5.10.4 BARGAINING POWER OF BUYERS 99
5.10.5 INTENSITY OF COMPETITIVE RIVALRY 99
5.11 PATENT ANALYSIS 100
FIGURE 28 PATENT APPLICATIONS FOR VACCINES, SEPTEMBER 2013–SEPTEMBER 2023 100
TABLE 27 INDICATIVE LIST OF PATENTS IN VACCINES MARKET 100
5.12 KEY CONFERENCES & EVENTS 101
TABLE 28 DETAILED LIST OF KEY CONFERENCES & EVENTS, 2023–2024 101
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 102
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 102
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINES 102
5.13.2 KEY BUYING CRITERIA 103
FIGURE 30 KEY BUYING CRITERIA FOR END USERS IN VACCINES MARKET 103
6 VACCINES MARKET, BY TECHNOLOGY 104
6.1 INTRODUCTION 105
TABLE 29 VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 105
6.2 CONJUGATE VACCINES 105
6.2.1 INCREASING PUBLIC-PRIVATE PARTNERSHIPS TO DRIVE MARKET 105
TABLE 30 VACCINES MARKET FOR CONJUGATE VACCINES, BY REGION, 2021–2028 (USD BILLION) 106
TABLE 31 NORTH AMERICA: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 107
TABLE 32 EUROPE: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 107
TABLE 33 ASIA PACIFIC: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 108
TABLE 34 LATIN AMERICA: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 108

6.3 RECOMBINANT VACCINES 108
6.3.1 LESSER POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES TO DRIVE MARKET 108
TABLE 35 EXAMPLES OF RECOMBINANT VACCINES 109
TABLE 36 VACCINES MARKET FOR RECOMBINANT VACCINES, BY REGION, 2021–2028 (USD BILLION) 110
TABLE 37 NORTH AMERICA: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 110
TABLE 38 EUROPE: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 111
TABLE 39 ASIA PACIFIC: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 111
TABLE 40 LATIN AMERICA: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 112
6.4 INACTIVATED & SUBUNIT VACCINES 112
6.4.1 EASE OF STORAGE AND TRANSPORTATION TO DRIVE MARKET 112
TABLE 41 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES 113
TABLE 42 VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY REGION, 2021–2028 (USD BILLION) 114
TABLE 43 NORTH AMERICA: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 114
TABLE 44 EUROPE: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 115
TABLE 45 ASIA PACIFIC: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 115
TABLE 46 LATIN AMERICA: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 116
6.5 LIVE ATTENUATED VACCINES 116
6.5.1 HIGH COST OF STORAGE AND LIMITED FINANCIAL RESOURCES OF DISTRIBUTORS TO LIMIT MARKET 116
TABLE 47 EXAMPLES OF LIVE ATTENUATED VACCINES 117
TABLE 48 VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY REGION, 2021–2028 (USD BILLION) 117
TABLE 49 NORTH AMERICA: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 118
TABLE 50 EUROPE: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 118
TABLE 51 ASIA PACIFIC: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 119
TABLE 52 LATIN AMERICA: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 119
6.6 TOXOID VACCINES 119
6.6.1 RISING PREVALENCE OF BACTERIAL INFECTIONS AMONG INFANTS AND CHILDREN TO DRIVE MARKET 119
TABLE 53 EXAMPLES OF TOXOID VACCINES 120
TABLE 54 VACCINES MARKET FOR TOXOID VACCINES, BY REGION, 2021–2028 (USD BILLION) 120
TABLE 55 NORTH AMERICA: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 121
TABLE 56 EUROPE: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 121
TABLE 57 ASIA PACIFIC: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 122
TABLE 58 LATIN AMERICA: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 122
6.7 VIRAL VECTOR VACCINES 123
6.7.1 INCREASING INVESTMENT IN NOVEL VACCINE DEVELOPMENT TO DRIVE MARKET 123
TABLE 59 VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY REGION, 2021–2028 (USD BILLION) 123
TABLE 60 NORTH AMERICA: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 124
TABLE 61 EUROPE: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 124
TABLE 62 ASIA PACIFIC: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 125
TABLE 63 LATIN AMERICA: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 125
6.8 M-RNA VACCINES 126
6.8.1 INCREASING INVESTMENT IN M-RNA VACCINE DEVELOPMENT TO DRIVE MARKET 126
TABLE 64 VACCINES MARKET FOR M-RNA VACCINES, BY REGION, 2021–2028 (USD BILLION) 127
TABLE 65 NORTH AMERICA: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 127
TABLE 66 EUROPE: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 128
TABLE 67 ASIA PACIFIC: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 128
TABLE 68 LATIN AMERICA: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 129
6.9 OTHER VACCINES 129
TABLE 69 VACCINES MARKET FOR OTHER VACCINES, BY REGION, 2021–2028 (USD BILLION) 130
TABLE 70 NORTH AMERICA: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 130
TABLE 71 EUROPE: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 131
TABLE 72 ASIA PACIFIC: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 131
TABLE 73 LATIN AMERICA: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 132

7 VACCINES MARKET, BY TYPE 133
7.1 INTRODUCTION 134
TABLE 74 VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 134
7.2 MONOVALENT VACCINES 134
7.2.1 INCREASING INVESTMENT IN R&D AND RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 134
TABLE 75 EXAMPLES OF MONOVALENT VACCINES 135
TABLE 76 VACCINES MARKET FOR MONOVALENT VACCINES, BY REGION, 2021–2028 (USD BILLION) 136
TABLE 77 NORTH AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 136
TABLE 78 EUROPE: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 137
TABLE 79 ASIA PACIFIC: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 137
TABLE 80 LATIN AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 138
7.3 MULTIVALENT VACCINES 138
7.3.1 INCREASED NEED FOR IMMUNIZATION AND COST-EFFECTIVENESS TO DRIVE MARKET 138
TABLE 81 EXAMPLES OF MULTIVALENT VACCINES 139
TABLE 82 VACCINES MARKET FOR MULTIVALENT VACCINES, BY REGION, 2021–2028 (USD BILLION) 140
TABLE 83 NORTH AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 140
TABLE 84 EUROPE: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 141
TABLE 85 ASIA PACIFIC: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 141
TABLE 86 LATIN AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 142
8 VACCINES MARKET, BY DISEASE INDICATION 143
8.1 INTRODUCTION 144
TABLE 87 VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 144
8.2 PNEUMOCOCCAL DISEASE 144
8.2.1 INCREASING INCIDENCE OF PNEUMONIA IN CHILDREN TO DRIVE MARKET 144
TABLE 88 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL DISEASE VACCINES 145
TABLE 89 VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2021–2028 (USD BILLION) 146
TABLE 90 NORTH AMERICA: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 146
TABLE 91 EUROPE: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 147

TABLE 92 ASIA PACIFIC: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 147
TABLE 93 LATIN AMERICA: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 148
8.3 INFLUENZA 148
8.3.1 RISING NEED FOR IMMUNIZATION AGAINST VIRAL INFECTIONS TO DRIVE MARKET 148
TABLE 94 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES 149
TABLE 95 VACCINES MARKET FOR INFLUENZA, BY REGION, 2021–2028 (USD BILLION) 150
TABLE 96 NORTH AMERICA: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021–2028 (USD BILLION) 150
TABLE 97 EUROPE: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021–2028 (USD BILLION) 151
TABLE 98 ASIA PACIFIC: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021–2028 (USD BILLION) 151
TABLE 99 LATIN AMERICA: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021–2028 (USD BILLION) 152
8.4 COMBINATION VACCINES 152
8.4.1 GROWING DEMAND FOR ALL-IN-ONE VACCINE TO DRIVE MARKET 152
TABLE 100 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES 153
TABLE 101 VACCINES MARKET FOR COMBINATION VACCINES, BY REGION, 2021–2028 (USD BILLION) 154
TABLE 102 NORTH AMERICA: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 154
TABLE 103 EUROPE: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 155
TABLE 104 ASIA PACIFIC: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 155
TABLE 105 LATIN AMERICA: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 156
8.5 HPV 156
8.5.1 GROWING INCIDENCE OF SEXUALLY TRANSMITTED DISEASES TO DRIVE MARKET 156
TABLE 106 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES 157
TABLE 107 VACCINES MARKET FOR HPV, BY REGION, 2021–2028 (USD BILLION) 158
TABLE 108 NORTH AMERICA: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION) 158
TABLE 109 EUROPE: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION) 159
TABLE 110 ASIA PACIFIC: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION) 159
TABLE 111 LATIN AMERICA: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION) 160
8.6 MENINGOCOCCAL DISEASE 160
8.6.1 INCREASING INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS TO DRIVE MARKET 160
TABLE 112 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES 161
TABLE 113 VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2021–2028 (USD BILLION) 161
TABLE 114 NORTH AMERICA: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 162
TABLE 115 EUROPE: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 162
TABLE 116 ASIA PACIFIC: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 163
TABLE 117 LATIN AMERICA: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION) 163
8.7 HERPES ZOSTER 163
8.7.1 INCREASING INVESTMENT IN NOVEL VACCINE DEVELOPMENT TO DRIVE MARKET 163
TABLE 118 VACCINES MARKET FOR HERPES ZOSTER, BY REGION, 2021–2028 (USD BILLION) 164
TABLE 119 NORTH AMERICA: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021–2028 (USD BILLION) 165
TABLE 120 EUROPE: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021–2028 (USD BILLION) 165
TABLE 121 ASIA PACIFIC: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021–2028 (USD BILLION) 166
TABLE 122 LATIN AMERICA: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021–2028 (USD BILLION) 166
8.8 ROTAVIRUS 166
8.8.1 GROWING FOCUS OF GOVERNMENT AND NON-GOVERNMENT BODIES ON ROTAVIRUS PREVENTION TO DRIVE MARKET 166
TABLE 123 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES 167
TABLE 124 VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2021–2028 (USD BILLION) 167
TABLE 125 NORTH AMERICA: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021–2028 (USD BILLION) 168
TABLE 126 EUROPE: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021–2028 (USD BILLION) 168
TABLE 127 ASIA PACIFIC: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021–2028 (USD BILLION) 169
TABLE 128 LATIN AMERICA: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021–2028 (USD BILLION) 169
8.9 MMR 170
8.9.1 RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA TO DRIVE MARKET 170
TABLE 129 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES 170
TABLE 130 VACCINES MARKET FOR MMR, BY REGION, 2021–2028 (USD BILLION) 171
TABLE 131 NORTH AMERICA: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION) 171
TABLE 132 EUROPE: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION) 172
TABLE 133 ASIA PACIFIC: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION) 172
TABLE 134 LATIN AMERICA: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION) 173
8.10 VARICELLA 173
8.10.1 INCREASING PROMOTION OF IMMUNIZATION PROGRAMS TO DRIVE MARKET 173
TABLE 135 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES 173
TABLE 136 VACCINES MARKET FOR VARICELLA, BY REGION, 2021–2028 (USD BILLION) 174
TABLE 137 NORTH AMERICA: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021–2028 (USD BILLION) 174
TABLE 138 EUROPE: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021–2028 (USD BILLION) 175
TABLE 139 ASIA PACIFIC: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021–2028 (USD BILLION) 175
TABLE 140 LATIN AMERICA: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021–2028 (USD BILLION) 176
8.11 HEPATITIS 176
8.11.1 LOW SOCIO-ECONOMIC STANDARDS OF LIVING AND HIGH CONTAMINATION IN DRINKING WATER TO DRIVE MARKET 176
TABLE 141 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES 177
TABLE 142 VACCINES MARKET FOR HEPATITIS, BY REGION, 2021–2028 (USD MILLION) 177
TABLE 143 NORTH AMERICA: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021–2028 (USD BILLION) 178
TABLE 144 EUROPE: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021–2028 (USD BILLION) 178
TABLE 145 ASIA PACIFIC: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021–2028 (USD BILLION) 179
TABLE 146 LATIN AMERICA: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021–2028 (USD BILLION) 179
8.12 DTP 180
8.12.1 INCREASED OCCURRENCE OF DIPHTHERIA, TETANUS, AND PERTUSSIS IN EMERGING ECONOMIES TO DRIVE MARKET 180
TABLE 147 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES 180
TABLE 148 VACCINES MARKET FOR DTP, BY REGION, 2021–2028 (USD BILLION) 181
TABLE 149 NORTH AMERICA: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION) 181
TABLE 150 EUROPE: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION) 182
TABLE 151 ASIA PACIFIC: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION) 182
TABLE 152 LATIN AMERICA: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION) 183
8.13 POLIO 183
8.13.1 INCREASING GOVERNMENT INITIATIVES AND IMMUNIZATION PROGRAMS TO DRIVE MARKET 183
TABLE 153 VACCINES MARKET FOR POLIO, BY REGION, 2021–2028 (USD BILLION) 184
TABLE 154 NORTH AMERICA: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021–2028 (USD BILLION) 185
TABLE 155 EUROPE: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021–2028 (USD BILLION) 185
TABLE 156 ASIA PACIFIC: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021–2028 (USD BILLION) 186
TABLE 157 LATIN AMERICA: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021–2028 (USD BILLION) 186
8.14 OTHER DISEASE INDICATIONS 186
FIGURE 31 NUMBER OF COVID-19 CASES IN US, 2020–2023 187
TABLE 158 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS 187
TABLE 159 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2021–2028 (USD BILLION) 188
TABLE 160 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION) 188
TABLE 161 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION) 189
TABLE 162 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION) 189
TABLE 163 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION) 190
9 VACCINES MARKET, BY ROUTE OF ADMINISTRATION 191
9.1 INTRODUCTION 192
TABLE 164 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 192
9.2 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 192
9.2.1 EASIER ABSORPTION INTO BLOODSTREAM AND BETTER IMMUNE RESPONSE TO DRIVE MARKET 192
TABLE 165 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 193
TABLE 166 VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY REGION, 2021–2028 (USD BILLION) 194
TABLE 167 NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 194
TABLE 168 EUROPE: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 195
TABLE 169 ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 195
TABLE 170 LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 196
9.3 ORAL ADMINISTRATION 196
9.3.1 EASE OF ADMINISTRATION AND REDUCED RISK OF BLOOD-TRANSMITTED INFECTIONS TO DRIVE MARKET 196
TABLE 171 VACCINES MARKET FOR ORAL ADMINISTRATION, BY REGION, 2021–2028 (USD BILLION) 197
TABLE 172 NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 197
TABLE 173 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 198
TABLE 174 ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 198
TABLE 175 LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 199
9.4 OTHER ROUTES OF ADMINISTRATION 199
TABLE 176 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2021–2028 (USD BILLION) 200
TABLE 177 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 200
TABLE 178 EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 201
TABLE 179 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 201
TABLE 180 LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION) 202
10 VACCINES MARKET, BY END USER 203
10.1 INTRODUCTION 204
TABLE 181 VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 204
10.2 PEDIATRIC VACCINES 204
10.2.1 INCREASED INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT BODIES TO DRIVE MARKET 204
TABLE 182 VACCINES MARKET FOR PEDIATRIC VACCINES, BY REGION, 2021–2028 (USD BILLION) 205
TABLE 183 NORTH AMERICA: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 206
TABLE 184 EUROPE: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 206
TABLE 185 ASIA PACIFIC: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 207
TABLE 186 LATIN AMERICA: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 207
10.3 ADULT VACCINES 207
10.3.1 ADULT VACCINES SEGMENT TO COMMAND LARGER MARKET SHARE DURING FORECAST PERIOD 207
TABLE 187 VACCINES MARKET FOR ADULT VACCINES, BY REGION, 2021–2028 (USD BILLION) 209
TABLE 188 NORTH AMERICA: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 209
TABLE 189 EUROPE: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 210
TABLE 190 ASIA PACIFIC: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 210
TABLE 191 LATIN AMERICA: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION) 211
11 VACCINES MARKET, BY REGION 212
11.1 INTRODUCTION 213
TABLE 192 VACCINES MARKET, BY REGION, 2021–2028 (USD BILLION) 213
11.2 NORTH AMERICA 213
FIGURE 32 NORTH AMERICA: VACCINES MARKET SNAPSHOT 214
TABLE 193 NORTH AMERICA: VACCINES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 215
TABLE 194 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 215
TABLE 195 NORTH AMERICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 216
TABLE 196 NORTH AMERICA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 216
TABLE 197 NORTH AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 217
TABLE 198 NORTH AMERICA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 217
11.3 NORTH AMERICA: RECESSION IMPACT 217
11.3.1 US 218
11.3.1.1 US to dominate North American vaccines market during forecast period 218
TABLE 199 US: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 219
TABLE 200 US: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 219
TABLE 201 US: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 220
TABLE 202 US: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 220
TABLE 203 US: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 221
11.3.2 CANADA 221
11.3.2.1 High incidence of infectious diseases to drive market 221
TABLE 204 CANADA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 222
TABLE 205 CANADA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 222
TABLE 206 CANADA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 223
TABLE 207 CANADA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 223
TABLE 208 CANADA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 224
11.4 EUROPE 224
TABLE 209 EUROPE: VACCINES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 224
TABLE 210 EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 225
TABLE 211 EUROPE: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 225
TABLE 212 EUROPE: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 226
TABLE 213 EUROPE VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 226
TABLE 214 EUROPE: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 227
11.5 EUROPE: RECESSION IMPACT 227
11.5.1 GERMANY 227
11.5.1.1 Significant R&D investments and growing biotechnology industry to drive market 227
TABLE 215 GERMANY: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 229
TABLE 216 GERMANY: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 229
TABLE 217 GERMANY: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 230
TABLE 218 GERMANY: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 230
TABLE 219 GERMANY: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 231
11.5.2 UK 231
11.5.2.1 Launch of new products and increased funding by government and non-government organizations to drive market 231
TABLE 220 UK: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 232
TABLE 221 UK: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 232
TABLE 222 UK: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 233
TABLE 223 UK: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 233
TABLE 224 UK: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 234
11.5.3 FRANCE 234
11.5.3.1 Favorable government initiatives for mass immunization to drive market 234
TABLE 225 FRANCE: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 235
TABLE 226 FRANCE: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 235
TABLE 227 FRANCE: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 236
TABLE 228 FRANCE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 236
TABLE 229 FRANCE: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 237
11.5.4 ITALY 237
11.5.4.1 Higher investments by companies for increased production capacities to drive market 237
TABLE 230 ITALY: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 238
TABLE 231 ITALY: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 238
TABLE 232 ITALY: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 239
TABLE 233 TALY: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 239
TABLE 234 ITALY: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 240
11.5.5 SPAIN 240
11.5.5.1 Rising investments in vaccine development by private organizations to drive market 240
TABLE 235 SPAIN: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 241
TABLE 236 SPAIN: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 241
TABLE 237 SPAIN: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 242
TABLE 238 SPAIN: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 242
TABLE 239 SPAIN: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 243
11.5.6 REST OF EUROPE 243
TABLE 240 REST OF EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 244
TABLE 241 REST OF EUROPE: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 244
TABLE 242 REST OF EUROPE: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 245
TABLE 243 REST OF EUROPE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 245
TABLE 244 REST OF EUROPE: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 246
11.6 ASIA PACIFIC 246
FIGURE 33 ASIA PACIFIC: VACCINES MARKET SNAPSHOT 247
TABLE 245 ASIA PACIFIC: VACCINES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 248
TABLE 246 ASIA PACIFIC: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 248
TABLE 247 ASIA PACIFIC: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 249
TABLE 248 ASIA PACIFIC: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 249
TABLE 249 ASIA PACIFIC: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 250
TABLE 250 ASIA PACIFIC: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 250

11.7 ASIA PACIFIC: RECESSION IMPACT 250
11.7.1 JAPAN 251
11.7.1.1 Increasing government initiatives for improving quality of vaccines to drive market 251
TABLE 251 JAPAN: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 251
TABLE 252 JAPAN: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 252
TABLE 253 JAPAN: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 252
TABLE 254 JAPAN: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 253
TABLE 255 JAPAN: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 253
11.7.2 SOUTH KOREA 253
11.7.2.1 Strong government strategies for improved vaccine hubs to drive market 253
TABLE 256 SOUTH KOREA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 254
TABLE 257 SOUTH KOREA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 255
TABLE 258 SOUTH KOREA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 255
TABLE 259 SOUTH KOREA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 256
TABLE 260 SOUTH KOREA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 256
11.7.3 CHINA 256
11.7.3.1 Growing investments in biotechnology sector to drive market 256
TABLE 261 CHINA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 257
TABLE 262 CHINA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 257
TABLE 263 CHINA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 258
TABLE 264 CHINA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 258
TABLE 265 CHINA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 259
11.7.4 INDIA 259
11.7.4.1 Increasing government initiatives and development of new and improved vaccines to drive market 259
TABLE 266 INDIA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 260
TABLE 267 INDIA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 260
TABLE 268 INDIA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 261
TABLE 269 INDIA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 261
TABLE 270 INDIA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 262
11.7.5 REST OF ASIA PACIFIC 262
TABLE 271 REST OF ASIA PACIFIC: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 263
TABLE 272 REST OF ASIA PACIFIC: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 263
TABLE 273 REST OF ASIA PACIFIC: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 264
TABLE 274 REST OF ASIA PACIFIC: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 264
TABLE 275 REST OF ASIA PACIFIC: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 265
11.8 LATIN AMERICA 265
TABLE 276 LATIN AMERICA: VACCINES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 265
TABLE 277 LATIN AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 266
TABLE 278 LATIN AMERICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 266
TABLE 279 LATIN AMERICA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 267
TABLE 280 LATIN AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 267
TABLE 281 LATIN AMERICA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 268

11.9 LATIN AMERICA: RECESSION IMPACT 268
11.9.1 BRAZIL 268
11.9.1.1 Rising focus on immunization programs by government and non-government bodies to drive market 268
TABLE 282 BRAZIL: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 269
TABLE 283 BRAZIL: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 269
TABLE 284 BRAZIL: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 270
TABLE 285 BRAZIL: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 270
TABLE 286 BRAZIL: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 271
11.9.2 MEXICO 271
11.9.2.1 Presence of well-trained health professionals and ethnically varied population base for clinical trials to drive market 271
TABLE 287 MEXICO: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 272
TABLE 288 MEXICO: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 272
TABLE 289 MEXICO: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 273
TABLE 290 MEXICO: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 273
TABLE 291 MEXICO: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 274
11.9.3 REST OF LATIN AMERICA 274
TABLE 292 REST OF LATIN AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 275
TABLE 293 REST OF LATIN AMERICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 275
TABLE 294 REST OF LATIN AMERICA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 276
TABLE 295 REST OF LATIN AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 276
TABLE 296 REST OF LATIN AMERICA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 277
11.10 MIDDLE EAST & AFRICA 277
11.10.1 MIDDLE EAST 277
11.10.1.1 Increasing prevalence of infectious diseases to drive market 277
TABLE 297 MIDDLE EAST: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 278
TABLE 298 MIDDLE EAST: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 278
TABLE 299 MIDDLE EAST: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 279
TABLE 300 MIDDLE EAST: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 279
TABLE 301 MIDDLE EAST: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 280
11.10.2 AFRICA 280
11.10.2.1 Availability of funds and grants from developed economies to drive market 280
TABLE 302 AFRICA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 280
TABLE 303 AFRICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 281
TABLE 304 AFRICA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 282
TABLE 305 AFRICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION) 282
TABLE 306 AFRICA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 283
11.10.3 MIDDLE EAST & AFRICA: RECESSION IMPACT 283
12 COMPETITIVE LANDSCAPE 284
12.1 INTRODUCTION 284
12.2 KEY STRATEGIES/RIGHT TO WIN 284
12.3 STRATEGIES OF KEY PLAYERS IN VACCINES MARKET 284
TABLE 307 STRATEGIES ADOPTED BY MAJOR PLAYERS IN VACCINES MARKET 284
12.4 REVENUE SHARE ANALYSIS 287
FIGURE 34 REVENUE SHARE ANALYSIS, 2020–2022 287
12.5 MARKET SHARE ANALYSIS 287
FIGURE 35 MARKET SHARE ANALYSIS OF MAJOR PLAYERS IN VACCINES MARKET, 2022 288
TABLE 308 DEGREE OF COMPETITION: VACCINES MARKET 288
12.6 COMPANY EVALUATION MATRIX 289
12.6.1 STARS 289
12.6.2 EMERGING LEADERS 289
12.6.3 PERVASIVE PLAYERS 289
12.6.4 PARTICIPANTS 290
FIGURE 36 COMPANY EVALUATION MATRIX, 2022 290
12.6.5 COMPANY FOOTPRINT 291
12.6.5.1 Product footprint 291
12.6.5.2 Regional footprint 292
12.7 START-UP/SME EVALUATION MATRIX 293
12.7.1 PROGRESSIVE COMPANIES 293
12.7.2 RESPONSIVE COMPANIES 293
12.7.3 DYNAMIC COMPANIES 293
12.7.4 STARTING BLOCKS 294
FIGURE 37 START-UP/SME EVALUATION MATRIX, 2022 294
12.7.5 COMPETITIVE BENCHMARKING 295
TABLE 309 DETAILED LIST OF KEY START-UPS/SMES 295
TABLE 310 TECHNOLOGY AND REGIONAL BENCHMARKING FOR START-UPS/SMES 295
12.8 COMPETITIVE SCENARIOS AND TRENDS 296
12.8.1 KEY PRODUCT LAUNCHES AND APPROVALS 296
TABLE 311 KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–SEPTEMBER 2023 296
12.8.2 KEY DEALS 297
TABLE 312 KEY DEALS, JANUARY 2021–SEPTEMBER 2023 297
12.8.3 OTHER KEY DEVELOPMENTS 298
TABLE 313 OTHER KEY DEVELOPMENTS, JANUARY 2021–SEPTEMBER 2023 298
13 COMPANY PROFILES 299
(Business overview, Products/Services/Solutions offered, Recent Developments, MNM view)*
13.1 KEY PLAYERS 299
13.1.1 PFIZER INC. 299
TABLE 314 PFIZER INC.: COMPANY OVERVIEW 299
FIGURE 38 PFIZER INC.: COMPANY SNAPSHOT (2022) 300
13.1.2 MERCK & CO., INC. 305
TABLE 315 MERCK & CO., INC.: COMPANY OVERVIEW 305
FIGURE 39 MERCK & CO. INC.: COMPANY SNAPSHOT (2022) 306
13.1.3 GSK PLC 310
TABLE 316 GSK PLC: COMPANY OVERVIEW 310
FIGURE 40 GSK PLC: COMPANY SNAPSHOT (2022) 311
13.1.4 SANOFI 317
TABLE 317 SANOFI: COMPANY OVERVIEW 317
FIGURE 41 SANOFI: COMPANY SNAPSHOT (2022) 318
13.1.5 CSL 322
TABLE 318 CSL: COMPANY OVERVIEW 322
FIGURE 42 CSL: COMPANY SNAPSHOT (2022) 323
13.1.6 EMERGENT 327
TABLE 319 EMERGENT: COMPANY OVERVIEW 327
FIGURE 43 EMERGENT: COMPANY SNAPSHOT (2022) 328
13.1.7 JOHNSON & JOHNSON SERVICES, INC. 330
TABLE 320 JOHNSON & JOHNSON SERVICES INC.: COMPANY OVERVIEW 330
FIGURE 44 JOHNSON & JOHNSON SERVICES INC: COMPANY SNAPSHOT (2022) 331
13.1.8 ASTRAZENECA 333
TABLE 321 ASTRAZENECA: COMPANY OVERVIEW 333
FIGURE 45 ASTRAZENECA: COMPANY SNAPSHOT (2022) 334
13.1.9 SERUM INSTITUTE OF INDIA PVT., LTD. 336
TABLE 322 SERUM INSTITUTE OF INDIA PVT., LTD.: COMPANY OVERVIEW 336
13.1.10 BAVARIAN NORDIC 341
TABLE 323 BAVARIAN NORDIC: COMPANY OVERVIEW 341
FIGURE 46 BAVARIAN NORDIC: COMPANY SNAPSHOT (2022) 341
13.1.11 MITSUBISHI TANABE PHARMA CORPORATION 345
TABLE 324 MITSUBISHI TANABE PHARMA CORPORATION: COMPANY OVERVIEW 345
13.1.12 DAIICHI SANKYO COMPANY, LIMITED 347
TABLE 325 DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW 347
FIGURE 47 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2022) 348

13.1.13 PANACEA BIOTEC 350
TABLE 326 PANACEA BIOTEC: COMPANY OVERVIEW 350
FIGURE 48 PANACEA BIOTEC: COMPANY SNAPSHOT (2022) 351
13.1.14 BIOLOGICAL E LIMITED 353
TABLE 327 BIOLOGICAL E LIMITED: COMPANY OVERVIEW 353
13.1.15 BHARAT BIOTECH 357
TABLE 328 BHARAT BIOTECH: COMPANY OVERVIEW 357
13.1.16 NOVAVAX 360
TABLE 329 NOVAVAX: COMPANY OVERVIEW 360
FIGURE 49 NOVAVAX, INC.: COMPANY SNAPSHOT (2022) 360
13.1.17 INOVIO PHARMACEUTICALS 363
TABLE 330 INOVIO PHARMACEUTICALS: COMPANY OVERVIEW 363
FIGURE 50 INOVIO PHARMACEUTICALS: COMPANY SNAPSHOT (2022) 363
13.2 OTHER PLAYERS 366
13.2.1 SINOVAC 366
13.2.2 INCEPTA PHARMACEUTICALS LTD. 367
13.2.3 VALNEVA SE 369
13.2.4 VBI VACCINES INC. 370
13.2.5 BIO FARMA 371
13.2.6 FSUE NPO MICROGEN 373
13.2.7 ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. 374
13.2.8 INDIAN IMMUNOLOGICALS LIMITED 375
*Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
14 APPENDIX 376
14.1 DISCUSSION GUIDE 376
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 380
14.3 CUSTOMIZATION OPTIONS 382
14.4 RELATED REPORTS 382
14.5 AUTHOR DETAILS 383

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のワクチン市場（～2028年）：技術別（遺伝子組換え、トキソイド、コンジュゲート、RNA）、種類別（単価、多価）、疾患別（肺炎球菌、インフルエンザ、DTP、HPV、MMR、新型コロナウイルス感染症）、投与経路別（IM、SC、経口）、エンドユーザー別（小児、成人）、地域別(Vaccines Market by Technology (Recombinant, Toxoid, Conjugate, RNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Influenza, DTP, HPV, MMR, COVID-19), Route of Administration (IM, SC, Oral), End user (Pediatric, Adult) & Region - Global Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp